NSE: ACUTAAS | BSE: 543349

Strong Performer, Getting Expensive

Download real time

1707.60 -1.60 (-0.09%)

85.86% Gain from 52W Low

124.6K NSE+BSE Volume

NSE 05 Dec, 2025 3:31 PM (IST)

13,980.3

Market Cap

High in industry

Beta 1Year

Very High Volatility

Acutaas Chemicals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ACUTAAS, BSE:543349 Acutaas Chemicals Ltd.

Search Inside the pdf :

Acutaas Chemicals Ltd.

27 Oct 2025

1707.60

-0.09%

Strong quarter with robust growth and margin expansion.

Accumulate: Acutaas Chemicals Ltd.

Recommendation Target

Deven Choksey

Acutas Chemicals delivered robust revenue and profit growth, driven by strong performance in API and specialty chemicals segment.

Acutaas Chemicals Ltd. has an average target of 1962.00 from 2 brokers.

Acutaas Chemicals Ltd.

23 Oct 2025

1707.60

-0.09%

Acutaas Chemicals: Q2FY26 Result Review

Buy: Acutaas Chemicals Ltd.

Target

IDBI Capital

Acutaas Chemicals registered a superlative performance in Q2FY26. Revenue, EBITDA and PAT registered strong growth of 24%,95% and 94% respectively on YoY terms. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 29%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the...

Acutaas Chemicals Ltd. has an average target of 1962.00 from 2 brokers.

Acutaas Chemicals Ltd.

31 Jul 2025

1707.60

-0.09%

Acutaas Chemicals: Q1FY26 Result Review

Buy: Acutaas Chemicals Ltd.

Target

IDBI Capital

Acutaas Chemicals registered a strong performance in Q1FY26. Revenue, EBITDA and PAT registered strong growth of 17%,73% and 218% respectively on YoY terms albeit from a weak base. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 23%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with...

Acutaas Chemicals Ltd. is trading above its 200 day SMA of 1316.9

Acutaas Chemicals Ltd.

24 Jul 2025

1707.60

-0.09%

Stock Flash

Buy: Acutaas Chemicals Ltd.

Deven Choksey

Acutaas Chemicals Limited (formerly known as Ami Organics Limited) has announced a strategic investment of up to INR 2 Bn in its wholly owned subsidiary, Acutaas Advance Material Limited (AAML), to support expansion in the semiconductor chemicals business.